Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 57Thoracic 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 17Triple Negative Breast Neoplasms 13Ovarian Neoplasms 2Breast Cancer Metastatic 2Uterine Cervical Neoplasms 1Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer 1Stomach Neoplasms 1Neoplasms 1HR+/HER2-breast Cancer 1HER2-negative Breast Cancer Brain Metastases 1Fludzoparib" and Anti-angiogenic 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Organoids 1Advanced Triple-Negative Breast Cancer 1Advanced Triple Negative Breast Cancer 1Advanced Breast Cancer 1

Interventions

pembrolizumab 28Trastuzumab 16Paclitaxel 14Docetaxel 12Cyclophosphamide 11Capecitabine 11Nivolumab 9fludarabine 7Carboplatin 7Oxaliplatin 6Magnetic Resonance Spectroscopy 6Cisplatin 6Specimen Handling 5Leucovorin 5Irinotecan 5Injections 5Gemcitabine 5Fluorouracil 5Bevacizumab 5atezolizumab 4aldesleukin 4Taxes 4Ipilimumab 4Fluorodeoxyglucose F18 4Drug Therapy 4Cetuximab 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4zanidatamab 3veliparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × apatinib × Breast × Clear all
NCT03384511 2018-02-20

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

Shandong Cancer Hospital and Institute

Phase 4 Completed
38 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡